型号:
产品价格:电议      采购度:1595      原产地:美洲
发布时间:2021/11/4 19:12:06 所属地区:国外 国外
简要描述:
Ginsenoside Rb1 Ginsenoside Rb2 是人参提取物的主要生物活性成分。Ginsenoside Rb2 可以上调 GPR120 基因表达。Ginsenoside Rb2 具有抗病毒作用。
Panax ginseng 的成分。Gin
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 11021-13-9
MCE 站:Ginsenoside Rb2
产品活性:Ginsenoside Rb2 是人参提取物的主要生物活性成分。Ginsenoside Rb2 可以上调 GPR120 基因表达。Ginsenoside Rb2 具有抗病毒作用。
研究领域:GPCR/G Protein | Anti-infection | Metabolic Enzyme/Protease
作用靶点:GPR120 | Influenza Virus | Endogenous Metabolite
In Vitro: Ginsenoside Rb2 pre-treatment enhances the anti-inflammatory effect of α-linolenic acid (ALA) and that the enhancing effect is strictly dependent on GPR120 activation. Ginsenoside Rb2 exerts anti-inflammatory effect in lipopolysaccharide (LPS)-stimulated mouse macrophage RAW264.7 cells in vitro by increasing GPR120 expression and subsequently enhancing ω-3 fatty acid-induced GPR120 activation. Ginsenoside Rb2 improves glucose metabolism in hepatocytes by activating AMPK and reduces cholesterol and triacylglycerol levels in 3T3-L1 cells by reducing oxidative damage. Ginsenoside Rb2 exerts anti-apoptosis effects in murine bone marrow-derived mesenchymal stem cells (BMMSCs). MTT assay results show no obvious cytotoxicity of Ginsenoside Rb2 (up to 100 μM) toward RAW264.7 cells in the absence or presence of ALA. The influence of Rb2 on GPR120 expression in RAW264.7 macrophages is investigated by treating the cells with Ginsenoside Rb2 (0.1-100 μM) for 12 h followed by harvesting and lysis. Subsequent Western blot analysis shows that expression of GPR120 is dose-dependently upregulated by Ginsenoside Rb2. Real-time PCR results indicate that incubation of RAW264.7 macrophages with Ginsenoside Rb2 (10 μM) for 12 h leads to a 2.8-fold increase in GPR120 mRNA expression. In addition, this increase in GPR120 expression stimulated by Ginsenoside Rb2 is time dependent and begins as early as 6 h. These results indicate that Rb2 upregulates GPR120 expression in a dose- and time-dependent manner in RAW264.7 macrophages.
In Vivo: Ginsenoside Rb2 is an antiviral reagent to protect against rotavirus (RV) infection. When various dosages of Ginsenoside Rb2 (25 to 250 mg/kg) are administered 3, 2 or 1 days before virus challenge, treatment with this Ginsenoside at the dosage of 75 mg/kg 3 days before virus infection most effectively reduces rotavirus (RV) -induced diarrhea. In addition, consecutive administration of Ginsenoside Rb2 (75 mg/kg) 3, 2, and 1 day before virus infection is more effective than single administration on day-3. The consecutive administration of Ginsenoside Rb2 also reduces virus titers in the bowels of RV-infected mice.
相关产品:Natural Product Library Plus | Bioactive Compound Library Plus | Anti-Infection Compound Library | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | Metabolism/Protease Compound Library | Natural Product Library | Antiviral Compound Library | Human Endogenous Metabolite Compound Library | Medicine Food Homology Compound Library | Terpenoids Library | Traditional Chinese Medicine Monomer Library | Food-Sourced Compound Library | Rapamycin | 3-Methyladenine | Acetylcysteine | 5-Fluorouracil | U0126-EtOH | ATP | Retinoic acid | Hydrocortisone | Docetaxel | Estradiol | Melatonin | Tunicamycin | Nicotinamide | Cytarabine | Isoprenaline hydrochloride | Prostaglandin E2 | Vadimezan | Acetaminophen | Curcumin | Favipiravir | (-)-Epigallocatechin Gallate | L-Ascorbic acid | β-Nicotinamide mononucleotide | Molnupiravir | Camptothecin | Calcitriol | DHEA | Aprotinin | Liothyronine | Luteolin
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:18:59
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品